60. **(NEW)** The method of claim 47, wherein the ultraviolet radiation absorbed by the skin of the mammal is less than a minimum erythemal dose for the mammal after a one hour exposure to the ultraviolet radiation.

61. **(NEW)** The method of claim 47, wherein the ultraviolet radiation absorbed by the skin of the mammal is less than a minimum erythemal dose for the mammal after a four hour exposure to the ultraviolet radiation.

62. **(NEW)** The method of claim 47, wherein the ultraviolet radiation absorbed by the skin of the mammal is less than a minimum erythemal dose for the mammal after an eight hour exposure to the ultraviolet radiation.

63. **(NEW)** The method of claim 47, wherein the mammal is human.

64. **(NEW)** The method of claim 47, wherein the mammal is a dog or a cat.

REMARKS

Claim 41 stands "allowable" if rewritten in independent form. The limitations of Claim 41 have been added to amended claim 5. Consequently, the applicant respectfully submits claim 5(41) is in condition for allowance.

Claims 6-17, 35-40 and 42 are dependent on claim 5(41) and hence, it is respectfully submitted are now in condition for allowance. Favorable action is requested.

Claim 47 stands "allowable."

Claims 53-64 have been added as dependent on claim 47. Consequently, it is respectfully submitted that claims 53-64 are likewise "allowable." Applicant requests favorable action thereon.

SUMMARY

It is further submitted that the application is now in condition for allowance, and early notice of the same is earnestly solicited. Should the Examiner have any questions, comments or suggestions in furtherance of the prosecution of this application, the Examiner is invited to contact the undersigned by telephone or facsimile.

An extension of three (3) months is requested and a Notification of Extension of Time under 37 C.F.R. § 1.136 with the appropriate fee of $460.00 is attached herewith.

Attached hereto is a marked-up version of the changes made to the claims by the current amendments. The attached pages are captioned **"Version with Markings to Show Changes Made."**

The Commissioner is hereby authorized to charge any fees or credit any overpayments to Deposit Account No. 02-0383 of Baker Botts L.L.P.

Respectfully submitted,

BAKER BOTTS L.L.P.

Date: 12/20/02

Bruce W. Slayden II
Reg. No. 33,790
One Shell Plaza
910 Louisiana Street
Houston, Texas 77002-4995
Telephone: 713.229.1786
Facsimile: 713.229.7886
ATTORNEY FOR APPLICANTS

Version with Markings to Show Changes Made to Claims

In the Specification:

Please amend the paragraph beginning on Page 10, Line 13 as follows:

--The above described sunscreen formulations can be used in additional applications for treatment of conditions caused by ultraviolet radiation. Sunscreen formulations can be used to minimize or eliminate facial-oral herpes simplex recurrent herpes labialis or cold sores. Sunscreen formulations can be used to reduce or eliminate the occurrence of Lentigo solar, commonly referred to as "liver spots" or "coffin spots". Sunscreen formulations can be used to reduce or eliminate the occurrence of Cutis Rhomboidalis Nuchae. Sunscreen formulations can be used to reduce or eliminate the occurrence of Favre-Racouchot disease. Sunscreen formulations can be used to reduce or eliminate the occurrence of Solar Purpura (Batema's Senile Purpura). Sunscreen formulations can be used to reduce or eliminate the occurrence of Venous Lake. Sunscreen formulations can be used to reduce or eliminate the occurrence of stellate scars of the hands and forearms resulting from tearing of fragile photodamaged skin. Sunscreen formulations can be used to reduce or eliminate the occurrence of Chromic actinic dermatitis. Sunscreen formulations can be used to reduce or eliminate the occurrence of xeroderma pigmentosum. Sunscreen formulations can be used to reduce or eliminate the occurrence of solar urticaria. Sunscreen formulations can be used to reduce or eliminate the occurrence of chronic discoid lupus **[erythematosis]**<u>**erythematosis**</u>. Sunscreen formulations can be used to reduce or eliminate the occurrence of photoaging. Sunscreen formulations can be used to reduce or eliminate the occurrence of pellagra.--

In the Claims:

5(41). **(twice amended)** A method to reduce the absorption of ultraviolet radiation by the skin of a mammal, the method comprising:

providing a formulation comprising **[a]** nucleic acids **having one or more R-group substitutions; and a compound selected from the group consisting of phynylalanine, trytophan, tyrosine, keratin, albumin, collagen, elastin, riboflavin, and retonoic acid**; and

applying said formulation to the skin of a mammal to reduce the absorption of ultraviolet radiation by the skin of said mammal.

Please cancel claims 18-34 without prejudice or disclaimer.

35. **(amended)** The method of claim 5, wherein the nucleic acid**s** **[is]are** modified by ethylation, cross linking, ultraviolet induced cross-linking, or the formation of thymidine dimers.

36. **(amended)** The method of claim 5, wherein the nucleic acid**s** **[is]are** less than 100 base pairs.

37. **(amended)** The method of claim 5, wherein the nucleic acid**s** **[is]are** in a cholerestic liquid phase, a lyotropic liquid crystal phase, or a precholesteric phase.

38. **(amended)** The method of claim 5, wherein the nucleic acid**s** **[is]are** single stranded, double stranded, or triple stranded.

Please cancel claim 41 without prejudice or disclaimer.

Please cancel claims 43-46 without prejudice or disclaimer.

Please cancel claims 48-52 without prejudice or disclaimer.

53. **(NEW) The method of claim 47, wherein the nucleic acid is DNA.**

54. **(NEW) The method of claim 47, wherein the nucleic acid is DNA of an average size at least about 100 base pairs.**

55. **(NEW) The method of claim 47, wherein the ultraviolet radiation is UVB radiation.**

56. **(NEW) The method of claim 47, wherein applying said formulation to said mammal results in a reduction in the amount of ultraviolet radiation absorbed by the skin of said mammal.**

57. **(NEW) The method of claim 47, wherein applying said formulation to said mammal results in at least about a 90% reduction in the amount of ultraviolet radiation absorbed by the skin of said mammal.**

58. **(NEW) The method of claim 47, wherein applying said formulation results in at least about a 95% reduction in the amount of ultraviolet radiation absorbed by the skin of said mammal.**

59. **(NEW) The method of claim 47, wherein applying said formulation results in at least about a 99% reduction in the amount of ultraviolet radiation absorbed by the skin of said mammal.**

60. **(NEW) The method of claim 47, wherein the ultraviolet radiation absorbed by the skin of the mammal is less than a minimum erythemal dose for the mammal after a one hour exposure to the ultraviolet radiation.**

61. **(NEW) The method of claim 47, wherein the ultraviolet radiation absorbed by the skin of the mammal is less than a minimum erythemal dose for the mammal after a four hour exposure to the ultraviolet radiation.**

62. **(NEW) The method of claim 47, wherein the ultraviolet radiation absorbed by the skin of the mammal is less than a minimum erythemal dose for the mammal after an eight hour exposure to the ultraviolet radiation.**

63. **(NEW) The method of claim 47, wherein the mammal is human.**

64. **(NEW) The method of claim 47, wherein the mammal is a dog or a cat.**